Risankizumab (Skyrizi, AbbVie) is indicated for 'the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biological therapy, or if such therapies are not advisable'.
The dosage schedule is available in the summary of product characteristics for risankizumab 600-mg concentrate for solution for infusion and risankizumab 360-mg solution for injection in cartridge.
The list price of the 600‑mg concentrate solution for infusion used for induction treatment is £3,326.09. The list price of the on-body device with 360‑mg solution for injection for maintenance treatment is £3,326.09 (excluding VAT, BNF online, accessed September 2024).
The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.